Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BACE1 | P56817 | 1/20 | 0.36 |
| ▸ | LPL | P06858 | 1/20 | 0.34 |
| ▸ | LIPG | Q9Y5X9 | 1/20 | 0.34 |
| ▸ | EGFR | P00533 | 2/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | THRB | P10828 | 1/20 | 0.31 |
| ▸ | CA1 | P00915 | 1/20 | 0.30 |
| ▸ | CA2 | P00918 | 1/20 | 0.30 |
| ▸ | CA9 | Q16790 | 1/20 | 0.30 |
| ▸ | JAK2 | O60674 | 1/20 | 0.30 |
| ▸ | BTK | Q06187 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12092030 | 0.83 | LPL (0.36) | LPLLIPG | |
| SCHEMBL23409416 | 0.83 | LPL (0.36) | LPLLIPGEGFRJAK2BTK | |
| SCHEMBL30237337 | 0.83 | LPL (0.36) | LPLLIPGEGFRJAK2BTK | |
| SCHEMBL23712487 | 0.83 | LPL (0.36) | LPLLIPGEGFRJAK2BTK | |
| SCHEMBL30237388 | 0.81 | JAK2 (0.38) | EGFRALDH1A1CYP3A4THRBCA1 | |
| SCHEMBL23409410 | 0.81 | LPL (0.35) | LPLLIPGEGFRJAK2BTK | |
| SCHEMBL23409554 | 0.80 | LPL (0.34) | LPLLIPGEGFRJAK2BTK | |
| SCHEMBL23206151 | 0.80 | LPL (0.34) | LPLLIPGEGFRJAK2BTK | |
| SCHEMBL24616237 | 0.80 | LIPE (0.31) | EGFRALDH1A1CYP3A4CA1CA2 | |
| SCHEMBL30520493 | 0.80 | LIPE (0.31) | EGFRALDH1A1CYP3A4CA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210309632-A1 | 4-(3-CYANOPHENYL)-6-PYRIDINYLPYRIMIDINE MGLU5 MODULATORS | NXERA PHARMA UK LIMITED (GB) | 2021-10-07 | — | — | US | disclosed |
| US-9676745-B2 | 4-(3-cyanophenyl)-6-pyridinylpyrimidine mGlu5 modulators | HEPTARES THERAPEUTICS LIMITED (GB) | 2017-06-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210309632-A1 | 4-(3-CYANOPHENYL)-6-PYRIDINYLPYRIMIDINE MGLU5 MODULATORS | GRM5, GRM6, GRM2 | BACE1 1775/4885LPL 1073/4885LIPG 2273/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.